PAS
IOBT

PKS Advisory Services’s IO Biotech IOBT Stock Holding History

PKS Advisory Services’s Portfolio IOBT Stock Details IOBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-20,000
Closed -$12.2K – 247
2025
Q4 		$12.2K Buy
20,000
+500
+3% +$372 ﹤0.01% 255
2025
Q3 		$7.08K Buy
+19,500
New +$33.6K ﹤0.01% 245
2025
Q1 		– Sell
-16,000
Closed -$14.7K – 263
2024
Q4 		$14.7K Buy
+16,000
New +$15.9K ﹤0.01% 246

Other funds holding IOBT

IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return

PKS Advisory Services's IOBT Position: Q1 2026 in Review

PKS Advisory Services sold out of IO Biotech (IOBT) in Q1 2026, closing a stake of 20,000 shares — an estimated $12.2K sold.

PKS Advisory Services first reported a position in IOBT in Q4 2024 and held it in 3 quarters. The position peaked at $14.7K in Q4 2024. 12 funds tracked by Wall St. Rank hold IOBT as of Q1 2026.

  • PKS Advisory Services reported no remaining IO Biotech position as of Q1 2026 after selling out during the quarter.
  • PKS Advisory Services sold 20,000 IO Biotech shares in Q1 2026, an estimated $12.2K.
  • PKS Advisory Services first reported a position in IO Biotech in Q4 2024 and held it in 3 quarters.
  • PKS Advisory Services's IO Biotech position peaked at $14.7K in Q4 2024.
  • 12 funds tracked by Wall St. Rank held IO Biotech as of Q1 2026.

Based on PKS Advisory Services's 13F filing for Q1 2026, filed 13 May 2026.